CE

CELLUMED CO., LTD.

Develops bone grafts, artificial joints, and enzymes for the biopharmaceutical sector.

049180 | KO

Overview

Corporate Details

ISIN(s):
KR7049180003
LEI:
Country:
South Korea
Address:
서울특별시 금천구 디지털로 130 402(가산동, 에이스테크노타워 9차), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CELLUMED CO., LTD. is a biotechnology company specializing in the development and manufacturing of medical devices and biologics. A pioneer in tissue banking, the company provides a range of bone graft materials, including allografts and xenografts, supported by advanced tissue processing technologies. Its product portfolio also includes musculoskeletal medical devices, such as artificial knee joints. Additionally, Cellumed supplies high-quality enzymes essential for the production of RNA-based medicines and vaccines, catering to the biopharmaceutical sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-19 00:00
Share Issue/Capital Change
기타주요경영사항 (제3자배정 유상증자 소액공모 철회의 건)
Korean 6.5 KB
2025-09-19 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 31.4 KB
2025-09-19 00:00
Share Issue/Capital Change
[기재정정]소액공모공시서류(지분증권)
Korean 1.9 MB
2025-09-19 00:00
Share Issue/Capital Change
소액공모실적보고서
Korean 26.0 KB
2025-08-26 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 109.8 KB
2025-08-25 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (채권압류 및 전부명령 항고 취하의 건)
Korean 8.2 KB
2025-08-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 72.5 KB
2025-08-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (집행판결 청구소송 합의의 건)
Korean 13.8 KB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.2 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-07-28 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (특허권 압류명령)
Korean 12.3 KB
2025-07-25 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (채권압류 및 전부명령 판결에 대한 항고의 건)
Korean 10.0 KB
2025-07-11 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (주식압류명령의 판결에 대한 항고의 건)
Korean 9.3 KB
2025-06-13 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (채권압류 및 전부명령)
Korean 12.5 KB
2025-06-13 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (주식압류명령)
Korean 14.2 KB

Automate Your Workflow. Get a real-time feed of all CELLUMED CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CELLUMED CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CELLUMED CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.